Stocks
GlaxoSmithKline (GSK) EBITDA US GAAP (year values) |
|||||||||
| 2022 | 2022 | 2022 | 2023 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA, £ | ? | 8 805 000 000 | 8 601 000 000 | 8 805 000 000 | 9 412 000 000 | 9 083 000 000 | 7 762 000 000 | ||
| Changes by years, y/y, % | +14% | -2% | +2% | +7% | -3% | +4.3% | |||
GlaxoSmithKline. EBITDA US GAAP, £
GlaxoSmithKline. EBITDA US GAAP, changes, %
GlaxoSmithKline. EBITDA US GAAP, sum by quarters, £
GlaxoSmithKline (GSK) EBITDA US GAAP (quarter values) |
||||||||
| 2024Q2 | 2024Q1 | 2024Q3 | 2024Q2 | 2024Q3 | LTM ? | |||
| EBITDA, £ | ? | 2 854 000 000 | 2 796 000 000 | 1 171 000 000 | 2 624 000 000 | 1 171 000 000 | 7 762 000 000 | |
| Changes by years, y/y, % | +9% | +2% | -63% | 0% | -63% | |||
| Changes by quarters, q/q, % | +28% | -2% | -58% | +124% | -55% | |||
